Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 450a-1 is a human small non-coding RNA gene that codes for a microRNA known for its tumor-suppressive properties in various cancer types. It exerts its biological effects primarily by binding complementary sequences in target mRNAs, leading to their silencing. In lung cancer, miR-450a-1 inhibits cell proliferation and invasion by directly targeting and downregulating IRF2, while in breast carcinoma, it targets CREB1 to suppress oncogenic signaling and cancer stem cell properties. Its role in embryonic development and other physiological processes is increasingly recognized, making it a subject of interest for both disease biomarker development and future therapeutic strategies.
Gene regulation via sequence-specific binding to complementary mRNA (3' UTR), causing mRNA degradation or translational repression. Suppression of specific oncogenic targets such as IRF2 (Interferon regulatory factor 2) and CREB1 (cAMP response element-binding protein 1).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 450a-1 (MIR450A1 (miR-450a-1)).